COG Nordics 2024 Meeting Review

April 2024 saw the PBC Group host the inaugural Clinical Outsourcing Group Nordics conference. This took place at the Scandic Copenhagen, Denmark. The 2-day meeting covered a range of topics related to clinical trials and outsourcing. Featuring keynote speeches from industry experts on trends in the CRO landscape, patient engagement, financing and budgeting, and much more. There was an emphasis on early-stage clinical development, with discussion around first-in-human, and phase I trial design considerations.

Heike Schön, Managing Director, Lumis International

The conference opened with Trial Nation’s Marianne Pilgaard keynote on the Danish Life Sciences landscape. Following keynotes came from Lumis International's Managing Director Heike Schön on recent trends reshaping the outsourcing landscape throughout Europe, and Globally.

Audience COG Nordics 2024

Further sessions delved into tactical areas like creating efficiencies through accurate curation of regulatory documents, presented by Tanja Jensen, and Matilde Thye Kyeiborg from Aixial Group. Leading to Sara Svedlund, Head of the Ribocure Clinic sharing the unique model Ribocure Pharmaceuticals have adopted by bringing their phase I clinic in-house.

C-Suite Panel Discussion on Investment Challenges for Biopharma

One of the many highlights from COG Nordics was the C-Suite panel discussion on the challenges, and sourcing opportunities for biopharma funding in the region. Chaired by Sam Vakili of Invest.In.Tek, panellists included CEOs, & COOs from emerging biopharma.

Evening Drinks Reception & Quick-Fire Quiz

The agenda truly delivered insights across the clinical trial lifecycle. From research contracts Myrthe Trompert's keynote, to First-In-Human planning with Tetra Pharm Technologies', to key regulator insights with talks from Ditte Zerlang Andersen of the Danish Medicines Agency, and Gunilla Andrew-Nielsen of the Swedish Medicines Product Agency, the conference tackled critical areas for trial outsourcing, regulatory compliance, financing, and operations.

COG Nordics welcomed over 67% of attending companies from active trial sponsor, regulators, or research organisations, with key international players such as AstraZeneca, Novo Nordisk represented, as well as representatives from the region's emerging biopharma sector.

Of those who attended, 76% were Director level or above, and 24% sitting in other Senior Management roles.

COG Nordics will return next year taking place 1st & 2nd April 2025, in Malmö, Sweden.